NVP-CLR457
oral pan-class IA PI3K inhibitor Ph. I in advanced solid tumors opt. from previous clinical candidate J. Med. Chem, May 2, 2022 Novartis (NIBR), Basel, CH
Molecules of the Month - May 2022
Molecules of the Month
- pevonedistat
- compound 20
- NVP-CLR457
- TXA6101
- RLX-33
- INCB13739
- compound 4e
- MAGLi 432
- sudapyridine (WX-081)
- dorzagliatin